Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Ono Pharmaceutical divulges KDM5A inhibitors

Feb. 8, 2021

China NMPA approves phase III trial of orelabrutinib with R-CHOP for MCL

Feb. 5, 2021

CEACAM7 is a therapeutic target for CART therapy in PDAC

Feb. 5, 2021

University of South Australia discovers new candidate for glioblastoma

Feb. 5, 2021

New Aurora kinase inhibitors described by Wigen Biomedicine Technology

Feb. 5, 2021

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Feb. 4, 2021

Erlotinib plus anlotinib shows promise in EGFR-mutated NSCLC

Feb. 4, 2021

ABTL-0812 plus paclitaxel and carboplatin result in increased efficacy in NSCLC

Feb. 4, 2021

RCC-33 reduces tumor volume in mice inoculated with colorectal cancer cells

Feb. 4, 2021

Phase Ib data show lack of objective response for CMP-001 plus atezolizumab in NSCLC

Feb. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...